Publication | Open Access

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

ThrombosisMedicineHematologyHemostasisPharmacotherapyJoint BleedsCoagulopathyBleeding DisorderPharmacologyAnticoagulantHemophilia Patients